Mizuho Securities analyst Irina Koffler reiterated a Buy rating and $34 price target on Horizon Pharma (NASDAQ: HZNP), saying they ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Short Sales Trader Talk

Negative Press Doesn't Change UBS View on Horizon Pharma (HZNP)November 12, 2015 9:14 AM DepoMed (DEPO) Sell-Off on Horizon News a 'Buying Opportunity'- JanneyNovember 11, 2015 11:48 AM FBR Analyst Comments on Skirmish Between Express Scripts (ESRX) and Horizon Pharma (HZNP)November 11, 2015 11:29 AM Pre-Open Stock Movers 11/11: (RNDY) (ANFI) (ALRM) (JCP) Higher; (HZNP) (EVDY) (BOOT) (M) Lower (more...)November 11, 2015 9:25 AM Insys Therapeutics (INSY) Trades Lower in Sympathy with Horizon Pharma (HZNP)November 11, 2015 9:25 AM Wall Street ends lower as oil and retailers weighNovember 11, 2015 7:27 AM Horizon Pharma plc Provides Comment on Express Scripts' Business PracticesNovember 11, 2015 7:17 AM Horizon Pharma (HZNP) Enteres Collaboration with ALR for RAYOS Study in SLENovember 11, 2015 7:05 AM Horizon Pharma plc Announces Collaboration With Alliance for Lupus Research to Study RAYOS(R) (prednisone) Delayed-Release Tablets in Systemic Lupus ErythematosusNovember 11, 2015 7:01 AM Horizon Pharma (HZNP) Responds to Express Scripts' (ESRX) Lawsuit; Says Linden Care Isn't So-Called 'Captive Pharmacy'November 11, 2015 6:42 AM